局部晚期乳腺癌10次大分割放疗前瞻性2期试验6年结果
该前瞻性2期试验纳入59例II-IIIA期乳腺癌术后患者,采用34 Gy/10次/2周照射全乳/胸壁及引流淋巴结。
要点
- 34 Gy/10次/2周方案照射全乳/胸壁及引流淋巴结,中位随访77.11个月。
- 任何级别局部区域晚期毒性累积发生率43.4%(95% CI),3级乳房回缩1例(1.7%)。
核心结论
- 结果支持术后针对原发部位及引流淋巴结区域采用10次大分割放疗方案在局部晚期乳腺癌中的治疗活性。
研究设计与样本
- 前瞻性2期试验,2015年2月至2019年3月纳入59例II-IIIA期乳腺癌女性,中位年龄60岁(IQR 48.3-68.8岁)。
- 83%患者接受保乳手术,17%接受乳房切除;除乳房切除未重建或临时扩张器者外,患者按Harvard量表自评美容结局。
主要发现
- 中位随访77.11个月(范围24-102个月),任何级别局部区域晚期毒性累积发生率为43.4%(95% CI),乳房切除组为30.0%,保乳组为46.1%。
- 纤维化、毛细血管扩张和淋巴水肿的峰值2级事件各1例(1.7%);1例(1.7%)在36个月随访时发生3级乳房回缩。
- 美容结局优秀、良好、一般和差的比例分别为61.7%、25%、7.6%和5.7%。
- 72个月时,特异无病生存率为96.5%,无远处转移生存率为88%,总生存率为94.4%。
关键数值与推荐
- 放疗方案为34 Gy/10次/2周,照射全乳/胸壁及引流淋巴结。
临床怎么用
- 该10次大分割放疗方案可作为局部晚期乳腺癌术后照射原发部位及引流淋巴结区域的选项之一。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We report the 6-year results of a phase 2 study on hypofractionated radiation therapy targeting the primary and regional lymph nodes in 10 fractions. METHODS AND MATERIALS: A schedule of 34 Gy/10 fractions/2 weeks to the whole breast/chest wall and the draining lymph nodes was used. Both acute and late toxicities were collected. All patients but those who underwent mastectomy without reconstruction or with temporary expander were asked to rate their cosmetic outcome according to the Harvard scale. Toxicity was assessed weekly during radiation therapy (RT) and then at each follow-up (fup) examination. Cancer-related endpoints were evaluated from the date of RT start to the diagnosis of local relapse/distant metastases or the last fup. RESULTS: From February 2015 to March 2019, 59 women (median age, 60 years and IQR, 48.3-68.8 years) with stage II to IIIA breast cancer who underwent axillary dissection and conservative surgery (83%) or mastectomy (17%) were accrued. One patient was lost to fup immediately after the end of RT. At the median fup of 77.11 months (range, 24-102 months), the cumulative incidence of any grade locoregional late toxicity estimated with the Kaplan-Meier method is 43.4% (95% CI) (30.0% and 46.1% for patients undergone mastectomy and lumpectomy, respectively). Peak-2 events have been observed for fibrosis (1 patient, 1.7%), telangiectasia (1 patient, 1.7%), and lymphoedema (1 patient, 1.7%). One patient (1.7%) experienced grade 3 breast retraction at 36 months fup. The cosmetic outcome resulted in being excellent, good, fair, and poor in 61.7%, 25%, 7.6%, and 5.7%, respectively. At 72 months, the specific-disease-free survival was 96.5%; distant metastasis-free survival and overall survival rates were 88% and 94.4%, respectively. CONCLUSIONS: Our results support the activity of a 10-fractions hypo-RT schedule targeting the primary site as well as the draining lymph node stations after surgery for locally advanced breast cancer.
引用
- Pinnarò P, Takanen S, Marucci L, et al. Six-Year Results From a Prospective Phase 2 Trial of 10-Fraction Hypofractionated Radiation Therapy in Locally Advanced Breast Cancer. Pract Radiat Oncol. 2025. PMID: 40122204. doi:10.1016/j.prro.2025.03.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。